argenx N.V.'s position as the leading player in the FcRn inhibitor class has been cemented with regulators in the US giving the green light to a more convenient subcutaneous formulation of its big-selling generalized myasthenia gravis (gMG) treatment Vyvgart.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?